Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
about
Health response to Hajj mass gathering from emergency perspective, narrative reviewTechnical Development of a New Meningococcal Conjugate VaccineEpidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccinationEmergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina FasoInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyEmergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.Meningococcal disease and climate.Global practices of meningococcal vaccine use and impact on invasive disease.Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural MozambiqueA versatile PDMS/paper hybrid microfluidic platform for sensitive infectious disease diagnosis.Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria.Methods for identifying Neisseria meningitidis carriers: a multi-center study in the African meningitis belt.Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana.Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool.Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.Performance of small cluster surveys and the clustered LQAS design to estimate local-level vaccination coverage in MaliA randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Rise of the microbes.Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.Meningococcal vaccines: a neglected topic in travel medicine?Bioanalysis of meningococcal vaccines.New frontiers in meningococcal vaccines.Can we, should we, eradicate the meningococcus?Meningococcal disease: changes in epidemiology and prevention.Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).Immunology and world health: key contributions from the global community.Meningococcal vaccines: current issues and future strategies.The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative.Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.[Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].OUTBREAK OF CEREBROSPINAL MENINGITIS IN KEBBI STATE, NIGERIA.Travel-related Neisseria meningitidis serogroup W135 infection, France.[Meningitis epidemic: assessment of surveillance and treatment of cases in the health centers of a Burkina Faso district].
P2860
Q26744848-C237E125-F5CF-4585-8FF1-B1AC5C4A73A0Q26778279-2060AB60-8773-41FB-BD59-F3D998D1257AQ28659784-1DF6EDCE-2E34-49BB-A736-CA93E030C6B7Q28744396-40C3253F-A2A3-4573-A960-5FC3DA88DE5AQ28972389-2FD1DDBD-C42B-407F-B597-AC0D591DFA89Q30239049-8721F28F-D831-42B6-BA0D-C541923642CDQ33561983-5CE18D4B-DF76-4606-86DD-1CFA2D820247Q33850840-0EBC5C6A-F7A9-412A-84A8-EE9331CF0E00Q33939565-6CB6C376-C437-4F59-9949-403B83044D4DQ34089110-8FE3E20E-A31F-409F-A196-02A6911B0D01Q34267478-E41EFC1A-8B30-42A6-A9B6-9415F7C5274CQ34785389-4B24D2B8-C836-4A12-856E-FC65C6864266Q35029246-482E1B17-1826-4FA9-9A19-8764AA144E60Q35032544-E9784B46-8DCA-4F5B-86D7-B9492C25F3E6Q35064842-24A18144-0E95-44FC-8258-8962E4504F37Q35198778-9A6675C2-F192-4944-8394-19F3FE08B9D3Q36166629-3EAB06D1-3FD7-45FE-B69E-02443C12D44EQ36265032-3BB0B218-1F45-4275-B5B8-1303043618E7Q36265080-A9A51494-0BB7-45D7-B264-34987980515EQ36265100-BC9D14D0-8D80-4DBC-B44A-ADDF4FDDF8FDQ36265103-A8244BCA-1CE5-47C3-BB21-884F92B3B146Q36411416-D5353A13-2ADC-476B-AF5F-C15FB3D93B54Q36849830-0A19AA5B-3012-4D47-9FBC-929A54AC6666Q37014766-44B37A28-FE9E-4184-B5BF-F161F83114B4Q37340824-B9ECB354-850A-46CC-B9A8-B1CF7DE1F1D4Q37608305-805D074B-2D76-4685-AA2A-3436B2EF00EDQ37810253-B3A78E7E-0B0A-4226-AB24-0E9806C426D8Q37878480-6D7485C5-835F-4989-B6B8-50864647F77EQ38011316-8F381D99-A12E-40DD-83DF-35BD93235AEEQ38052545-9D5DD172-C1AF-44C6-8DF0-5F67F60A86E1Q38066532-6098EF83-D8CF-4663-9F12-349E29338202Q38079607-252DC7C7-4C51-4422-803B-25B1D800A7F0Q38120493-C15AA752-795F-456A-8E48-C9245BE05F04Q38126097-1B4EBF63-6212-4D46-9C9B-794EB28CD51FQ38870793-D3B113B0-5114-42AC-9B85-005407DA5E5BQ39045024-2497149D-49E5-451E-8226-C7C212E09860Q40045360-7A7B2E97-EB8C-463B-BEC4-832AA2F8C4DBQ41925840-FDA1E470-3B5E-482B-93EA-22A2EC714C32Q43088467-CC073398-7143-4939-B47C-2E27768A91C9Q43930523-B6F25FD1-6934-48B7-AF5E-6C81E14EB18C
P2860
Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@ast
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@en
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@nl
type
label
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@ast
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@en
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@nl
prefLabel
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@ast
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@en
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@nl
P2093
P1433
P1476
Epidemic meningitis due to Gro ...... lem with an imminent solution.
@en
P2093
F Marc LaForce
Mamoudou Djingarey
Neil Ravenscroft
Simonetta Viviani
P356
10.1016/J.VACCINE.2009.04.062
P407
P478
27 Suppl 2
P577
2009-05-27T00:00:00Z